Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Remitly Global Inc (RELY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Remitly Global Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $224.04 (market cap $29.60B), while Remitly Global Inc trades at $23.44 (market cap $4.97B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 6× Remitly Global Inc's market cap, and Remitly Global Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | RELY | |
|---|---|---|
Market Cap | $29.60B | $4.97B |
Sector | Health | Technology |
52-Week High | $491.22 | $25.93 |
52-Week Low | $205.48 | $12.20 |
Enterprise Value | $27.56B | $4.33B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $216.98, down 1.01% with bearish technical signals. The company shows strong revenue growth from $1.0B in 2022 to $3.7B in 2025, turning profitable with $314M net income. However, recent Q2 2026 earnings missed expectations, and multiple law firms are investigating potential securities fraud. Analyst consensus remains bullish with a $370.07 price target despite recent volatility.
The stock faces near-term pressure from legal investigations and earnings volatility, but strong fundamentals and analyst support suggest long-term potential. Key risks include legal outcomes and execution on growth targets, while the 71% upside to consensus target offers opportunity if the company can maintain its revenue trajectory.
RELY trades at $23.14, down 5.24% over 24 hours, but maintains a bullish technical signal with key support at $22. The company reported strong Q2 2026 results, beating EPS estimates with $0.93 actual versus $0.12 expected, and revenue growth of 20% year-over-year. Profitability has improved significantly, with net income margin reaching 16.85% in 2026 from negative margins in prior years. Recent news highlights expansion into new financial services like the Global Card and regulatory approvals in the UAE.
The outlook is positive, driven by robust earnings growth, market share gains, and strategic initiatives beyond core remittances. Risks include competitive pressures and execution of new business lines. Analyst consensus is strongly bullish with a $31 price target, suggesting substantial upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Remitly Global Inc
Remitly Global Inc provides integrated financial services to immigrants, including helping customers send money internationally in a quick, reliable, and more cost-effective manner by leveraging digital channels. It supports cross-border transmissions across the globe. Its revenue is generated on transaction fees charged to customers and foreign exchange spreads between the foreign exchange rate offered to customers and the foreign exchange rate on the company's currency purchases.
Read more on RELY →
